Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. - Wikidata - awgldk - TriplyDB

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.

http://www.wikidata.org/entity/Q34938807

about

Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 Adeno-associated virus for cystic fibrosis gene therapy Barriers to inhaled gene therapy of obstructive lung diseases: A review Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors Efficient non-viral ocular gene transfer with compacted DNA nanoparticles.Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina Heart failure management: the present and the future.AAV's anatomy: roadmap for optimizing vectors for translational success Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs.Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice.High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung.Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta)Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates Methods for gene transfer to the central nervous system.Advances in cell and gene-based therapies for cystic fibrosis lung disease Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques Acquisition of selective antitumoral effects of recombinant adeno-associated virus by genetically inserting tumor-targeting peptides into capsid proteins Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies.Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue Prediction of adeno-associated virus neutralizing antibody activity for clinical application.Gene transfer in the lung using recombinant adeno-associated virus The role of Rds in outer segment morphogenesis and human retinal disease.Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology.Gene therapy in heart failure.Lentivirus vector can be readministered to nasal epithelia without blocking immune responses Adeno-associated viral vectors show serotype specific transduction of equine joint tissue explants and cultured monolayers The promise of gene therapy for the treatment of epilepsy.Capsid antibodies to different adeno-associated virus serotypes bind common regions.Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.Humoral Immune Response to AAV.

P2860

Q24634560-5EEC470C-459B-4905-B48A-E2F480BA37EB Q26823156-ADB0956E-5687-4BCC-AAB7-152D75A1918A Q29248141-27CE8FBC-A7D1-417C-A894-40A2807DC566 Q30152887-B90688CD-AC36-4865-A629-2260267A0029 Q30539153-6EC6F0E2-B29C-413E-93AF-B58D36016E79 Q30650955-FD5FDEDE-9B06-49FF-954F-2E32E2DA9695 Q33267297-7CD8DD3E-BD0B-4A67-BEF0-9146AA7A3183 Q33510137-3804EEC4-B8CE-41C8-A41B-AF4E7F43B837 Q33605156-0642EA5A-7F7C-49EC-A445-107321F12BDC Q33659389-3DE5AC4D-68BB-4280-975A-61E11360925A Q33678893-53A73ED0-0238-4508-8D5A-2C013F758EAE Q33739804-7236B7A5-AD9D-4FA5-ACFB-62612BB0C7D1 Q33921035-91D5C2CF-BDE8-4593-A20C-1A6D52E8498A Q33930149-90365BAD-5351-42BE-A833-70BC530F95BF Q34384998-EB369019-24DC-4713-BD03-78164B5325F4 Q34845196-834EF1DD-BBDD-492A-BAB6-A9D7973F838C Q35101904-636CF9B2-D536-46E5-9E5E-A234BCDA3582 Q35568520-1D0C0837-DBE5-42A6-A56D-9B77D26D33D4 Q35665240-104DE115-252E-4A27-BEEC-2BFDFA76405F Q35823873-48C8D626-D256-4479-B53A-8EDAADB018FA Q35892068-3D25BC11-F16A-4B38-AEED-76294F2271DF Q35902332-B3C7B38F-CE74-496E-AFD9-70DBDA1841D1 Q36014033-CAA8512D-C000-476E-9607-68B6A8595B5C Q36114234-6770937C-CCA1-450E-B527-5C01F18954E4 Q36121666-808224EA-53D6-463F-A1F4-82519B620093 Q36142496-F439C87D-8861-4B3B-A684-316E50E992C6 Q36290649-FC4497D7-5EDE-4A66-8C69-EB24E5196954 Q36322970-C0CB2959-ECAB-493F-8FF8-1DBAA030DD41 Q36348346-CFB9A31F-D515-4D9A-A88F-8251F81FFBAA Q36364617-8FC7FD19-D55B-4465-AE0B-5BEA1332CD7E Q36674594-0557A885-BB95-45D9-8790-D108C3AFCB2E Q36825929-C3BAAD5D-F5BA-4209-80BA-4187C40D0333 Q36925619-E9C6C936-8953-4C5F-8970-A2739647D139 Q36944623-A5365853-11F8-4067-BA47-DCE8385C0108 Q36949698-7557F766-C289-46F0-BEFC-DF2E8B39D514 Q36972596-422370F0-F3BB-4513-B606-8CE4FB9FC324 Q37021317-1196221C-0DED-4682-9E15-4D4D0A3066D0 Q37123344-6A99D9C4-5B61-479B-9EE5-A25874A66504 Q37127246-45209D00-1E86-4644-ACAF-38052614E93D Q37236099-D839078A-3D17-4BDA-80AD-99E17EDABDFE

P2860

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.

http://www.wikidata.org/entity/Q34938807

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@ast

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@en

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@nl

type

label

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@ast

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@en

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@nl

prefLabel

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@ast

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@en

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@nl

P1433

Q34938807-3673B617-8417-4EC5-9C49-C0227D2D730D

P1476

Q34938807-6C79A8A8-AB44-4D10-A386-F3A61CFA568A

P2093

Q34938807-25D2CA1E-15C5-4F1B-9DD6-7C68C111B5B3

Q34938807-7D09B8D8-F957-4747-A0F6-18331A1A5C29

Q34938807-82ACDE13-0954-4E24-AFB6-6F5CDF2EE9FA

Q34938807-9051010E-54A8-4752-B413-51133F35759E

Q34938807-AC4BC7C5-BBC9-40FD-BA37-7BAA201C8480

Q34938807-CAFFEFF5-A1E6-42BB-8EF9-82C713160496

Q34938807-FA454DCF-B07D-4936-8DA4-722712210229

P2860

Q34938807-00934BFC-DCB2-480A-86BF-5D466F54AE7B

Q34938807-041B790D-D133-4FD7-B534-7ED51EDB148D

Q34938807-18FCAC86-55FD-4331-AA31-E96C75F88F3E

Q34938807-2159B32F-F0A9-4202-854A-ECB1DCC21261

Q34938807-27F089A1-E903-4B8A-8787-55A93BDFCCE5

Q34938807-363DEEB3-8A4B-49A5-8498-AD4E69F97ABB

Q34938807-37A8EF45-4E91-4D20-8091-2D54C248F457

Q34938807-46A3E9F7-F761-4A0C-B764-CFD6CB3A249C

Q34938807-6A0C4D2B-F263-4898-95BE-00459FFA1014

Q34938807-756BADF5-2F9A-4F88-A21A-50A2937A7D19

P304

Q34938807-8C4A289C-A654-4115-A0F8-4B1AFC0013D5

P31

Q34938807-E4E875BB-CF2C-471A-9B8D-71B73812CDBA

P356

Q34938807-42A1E993-50DF-4DFC-8AF4-83A6039A48BC

P433

Q34938807-738C4512-657D-480D-8A27-4D4189C34DD2

P478

Q34938807-99691344-508B-43F1-A24D-C32278F42F22

P577

Q34938807-2798E2E1-8A7F-44DB-80DB-9367DFF743A1

P5875

Q34938807-C758BD4B-122C-4D3B-AA49-E9557C17BE2A

P698

Q34938807-FD87EA4F-48DE-4369-8DC4-A6A5F7C90DD2

P921

Q34938807-000948E5-510F-4D69-997A-71695C76A78C

Q34938807-19F385D8-DE4C-4983-9DE5-E02132AA472F

Q34938807-97360341-BB70-4F7E-BF5D-BA8AAC6592D8

Q34938807-A0AF9315-AF19-4C1B-81CE-930AF0ABAE7B

P932

Q34938807-B8BA80D8-DF4A-48FB-A717-39D3CDDB783C

P356

HUM.2006.17.440

P1433

Human Gene Therapy

P1476

Prevalence of neutralizing ant ...... ene therapy using AAV vectors.

@en

P2093

A Dusty Miller

http://www.w3.org/2001/XMLSchema#string

Bonnie Ramsey

http://www.w3.org/2001/XMLSchema#string

Christine L Halbert

http://www.w3.org/2001/XMLSchema#string

Julia Emerson

http://www.w3.org/2001/XMLSchema#string

Moira L Aitken

http://www.w3.org/2001/XMLSchema#string

Ronald L Gibson

http://www.w3.org/2001/XMLSchema#string

Sharon McNamara

http://www.w3.org/2001/XMLSchema#string

P2860

Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors

Characteristics of a human cell line transformed by DNA from human adenovirus type 5

Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.

Immune responses to adenovirus and adeno-associated virus in humans.

Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses

Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques.

P304

440-447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2006.17.440

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7169127

http://www.w3.org/2001/XMLSchema#string

P698

16610931

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

vector-borne disease

P932

4292890

http://www.w3.org/2001/XMLSchema#string